Horizon’s Joel White spoke with Inside Health Policy Senator Bernie Sanders’ actions surrounding his proposals to lower drug costs and
Horizon Government Affairs’ Joel White told Inside Drug Pricing the Biden administration may be willing to produce a new plan for drug price control, but Sanders’ commitment to withholding the approval of key health appointees is a weighty decision.
Sanders’ agenda comes as lawmakers pursue bipartisan PBM and other drug-pricing reforms. White said that many of Sanders’ drug pricing proposals highlighted in the op-ed are not likely to move forward with the expected Senate package to reform PBMs and streamline generic drug access.
“I think some of the things that Bernie Sanders talks about probably take away votes… and I think Schumer wants to get this all figured out, and eventually bring it to the floor this fall,” White told IDP